Latest stories on NVO
Lilly's retatrutide beats Novo’s Ozempic in late-stage trial
Seeking Alpha68 · bullishproduct/pr
Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick
Seeking Alpha63 · neutralanalyst
Sector Update: Healthcare Stocks Decline Tuesday Afternoon
Fidelity News44 · neutralgeneral
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?
The Motley Fool55 · neutralanalyst
Judge rejects Novo Nordisk bid to block Eli Lilly weight-loss ads - qz.com
Quartz44 · neutralgeneral
U.S. Judge Denies Novo Nordisk's Bid to Halt Eli Lilly Ads, NVO Stock Reacts
GuruFocus42 · neutralgeneral
Eli Lilly defeats Novo Nordisk attempt to halt weight-loss drug ads
Seeking Alpha58 · neutralgeneral
Novo Nordisk Loses Court Ruling Over Eli Lilly Obesity Drug Ads
Bloomberg42 · neutralgeneral
Moderately bullish activity in Novo Nordisk with shares up 0.24%
The Fly53 · neutralgeneral
US judge won’t block Eli Lilly ads for weight-loss drugs, rules against Novo Nordisk
Investing.com Markets50 · neutralgeneral
Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
GlobeNewswire64 · neutralproduct/pr
Novo Nordisk Details Progress In Dkk 15 Billion Share Buyback Programme 6
TipRanks71 · bullishgeneral
Novo Nordisk A/S - share repurchase programme
GlobeNewswire68 · bullishgeneral
Novo Nordisk A/S - share repurchase programme
StockTitan71 · bullishgeneral
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
MarketBeat63 · neutralanalyst
FDA approves Novo Nordisk’s Awiqli for type 2 diabetes in kids 10 and older
The Fly74 · bullishproduct/pr
What Is the Peptide Economy? Beyond the GLP-1 Boom
ETF Trends58 · neutralgeneral
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
The Motley Fool50 · neutralgeneral
Where Will Novo Stock Be in 10 Years?
The Motley Fool54 · neutralgeneral
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
The Motley Fool64 · neutralproduct/pr
Novo's CagriSema leads to 25% weight loss in women
Seeking Alpha74 · bullishproduct/pr
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data
TipRanks63 · neutralproduct/pr
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher
24/7 Wall St.64 · neutralproduct/pr
Novo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis
Quartz74 · bullishproduct/pr
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
CNBC74 · bullishproduct/pr